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Background: Regulated gene expression controls organismal development, and variation in regulatory patterns has
been implicated in complex traits. Thus accurate prediction of enhancers is important for further understanding of
these processes. Genome-wide measurement of epigenetic features, such as histone modifications and occupancy
by transcription factors, is improving enhancer predictions, but the contribution of these features to prediction accuracy is
not known. Given the importance of the hematopoietic transcription factor TAL1 for erythroid gene activation,
we predicted candidate enhancers based on genomic occupancy by TAL1 and measured their activity. Contributions of
multiple features to enhancer prediction were evaluated based on the results of these and other studies.
Results: TAL1-bound DNA segments were active enhancers at a high rate both in transient transfections of cultured cells
(39 of 79, or 56%) and transgenic mice (43 of 66, or 65%). The level of binding signal for TAL1 or GATA1 did
not help distinguish TAL1-bound DNA segments as active versus inactive enhancers, nor did the density of
regulation-related histone modifications. A meta-analysis of results from this and other studies (273 tested predicted
enhancers) showed that the presence of TAL1, GATA1, EP300, SMAD1, H3K4 methylation, H3K27ac, and CAGE tags at
DNase hypersensitive sites gave the most accurate predictors of enhancer activity, with a success rate over 80% and a
median threefold increase in activity. Chromatin accessibility assays and the histone modifications H3K4me1 and H3K27ac
were sensitive for finding enhancers, but they have high false positive rates unless transcription factor occupancy is also
included.
Conclusions: Occupancy by key transcription factors such as TAL1, GATA1, SMAD1, and EP300, along with evidence of
transcription, improves the accuracy of enhancer predictions based on epigenetic features.
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Accurate identification of cis-regulatory modules (CRMs),
such as enhancers, is essential for understanding mecha-
nisms of gene regulation, modeling regulation during differ-
entiation, and interpreting the effects of genetic variants
associated with complex traits. Challenges to meeting this
goal are formidable [1]. Most enhancers are in the portion
of the genome that does not code for proteins, and thus the* Correspondence: rch8@psu.edu
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unless otherwise stated.search space is enormous. No clear grammar for identifying
enhancers with a high success rate has been discovered,
and examination of the primary DNA sequence has limited
power for identifying enhancers [2]. Evidence of strong
evolutionary constraint [3-5] has consistently revealed
enhancers, but these are enriched for certain classes of
genes and tissues [6-8] and do not capture the full
spectrum of regulatory regions [9,10]. Application of
machine learning to find discriminatory patterns in
alignments of known regulatory regions has also been
successful [11-13]. Other methods for predicting en-
hancers based on conservation of noncoding regionsThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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proving enhancer prediction by methods inxc addition to
conservation or alignment-based approaches.
Understanding both biochemical mechanisms of en-
hancement and evolution of enhancers provides a basis for
more integrated approaches for their prediction. Enhancers
are clusters of transcription factor (TF) binding site motifs
in the DNA, and they are active when the TFs are bound
[15]. The complex of bound proteins tends to interact with
co-activators such as EP300 [16], and the TF-bound enhan-
cer is flanked by nucleosomes with characteristic histone
modifications, such as H3K4 monomethylation (H3K4me1)
and H3K27 acetylation (H3K27ac) [17-19]. These epigen-
etic features (proteins or modifications, including those in
chromatin, that lie on top of the DNA sequence) have been
used for predictions of enhancers. For instance, the
presence of H3K4me1 with little or no trimethylation
(H3K4me3) predicted enhancers with good accuracy
[20,21], enrichment by H3K27ac separated active en-
hancers from poised and inactive enhancers [18,22],
and the presence of EP300 identified heart enhancers with
high accuracy (75%) [8]. The combination of H3K4me1
plus EP300 was highly accurate (70% to 86%) for identifying
enhancers in melanocytes [23]. Using tissue-specific TFs
such as GATA1 in erythroid cells [24] and MYOD in
muscle cells [25] to predict enhancers had a good success
rate (40% to 50%) but lower than that for co-activators. For-
mal approaches to integrating multiple features for enhan-
cer prediction include a genome segmentation based on
multiple histone modifications and other features, utilizing
a hidden Markov model framework [26]. Two recent stud-
ies using massively parallel reporter assays (MPRAs) found
that 23% to 42% [27] or 26% [28] of these predicted en-
hancers were significantly active. Another approach used a
discriminatory machine-learning approach to integrate
multiple datasets and data types to predict and validate de-
velopmental enhancers [29].
While the power of epigenetic approaches for enhan-
cer prediction is clear, the features with the strongest
contributions to predictive accuracy are not known. Des-
pite the importance of TF occupancy in the mechanism
of enhancement, it has not been the focus of recent
methods for enhancer prediction, perhaps because of
the tissue-specificity of many TFs that play a role in en-
hancement. Nevertheless, many high-quality datasets of
TF occupancy are being determined genome-wide, many
TFs are active in multiple tissues (albeit not ubiqui-
tously), and co-activators such as EP300 are active in a
large number of tissues. Thus, it is important to examine
the role of TFs; this is most informative within a tract-
able developmental system and with multiple assays for
enhancement.
To address this need, we focused initially on occupancy
by TAL1, since this TF plays multiple key roles inhematopoiesis and is needed for differentiation of erythroid
progenitor cells into maturing erythroblasts [30]. Experi-
ments using conditional Tal1 knockout mutants and rescue
show that TAL1 is required for both specification and dif-
ferentiation of erythroid and megakaryocytic cells [31].
Furthermore, the co-binding of TAL1 with GATA1 is
strongly associated with gene induction [32-35]. Thus,
we began with high-quality datasets on TAL1 occu-
pancy in a mouse cell line model for maturing erythro-
blasts [36,37] as a single-factor predictor of erythroid
CRMs. Remarkably, a majority of the DNA segments
predicted as CRMs by this one factor and tested by re-
porter gene assays in either transfected cells in culture
or transgenic mouse embryos were active as enhancers.
Using ChIP-seq data for multiple epigenetic features
[10,38], we evaluated the contributions to enhancement
of these features on a meta-analysis of 273 DNA segments
tested for enhancement. Multiple features contributed to
accurate prediction of enhancer activity at TAL1-bound
DNA segments, and the presence together of TAL1,
GATA1, EP300, SMAD1, H3K4 methylation, H3K27ac,
and CAGE tags at DNase hypersensitive sites correctly pre-
dicted erythroid enhancers in over 80% of cases. In con-
trast, DNA segments in chromatin that is accessible or
marked with enhancer-associated histone modifications but
lacking binding by key TFs are rarely active as enhancers.
Results
Occupancy by TAL1 is a strong predictor of enhancer
activity
We began with the set of 4,915 DNA segments deter-
mined by ChIP-seq to be bound by TAL1 (TAL1 occu-
pied DNA segments or TAL1 OSs) (Table 1; Additional
file 1: Table S1) in G1E-ER4 cells treated with beta-
estradiol, which are a model for erythroblasts differentiat-
ing in response to restoration of GATA1 [39,40]. As
expected [41-43], the TAL1 OSs overlapped with other
epigenetic features suggestive of regulatory function, il-
lustrated by the example of a candidate enhancer in an
intron of the gene Gypc, which encodes the erythroid
membrane protein glycophorin C (Figure 1A). The vast
majority of TAL1 OSs were in regions of accessible chro-
matin (DNase I hypersensitive sites, DHSs; [36,44]) con-
taining histone modifications (HMs) associated with gene
regulatory regions (H3K27ac [45], H3K4me1 [36], and/or
H3K4me3 [36]; Figure 1B). Most peaks of TAL1 binding
coincided with binding by GATA1 [34,36] and the coacti-
vator EP300 [10,46] (Figure 1B). Only a small minority
had the H3K27me3 [36] or H3K9me3 [36] modifications
associated with gene repression (Figure 1B). The presence
of the promoter-associated histone mark H3K4me3 [20,47]
on the subset of TAL1 OSs that were close to transcription
start sites (TSS) (478 were within 1 kb of a TSS; Additional
file 2: Figure S1) showed that some TAL1 OSs are close to
Table 1 ChIP-seq datasets
Feature Cell line Number of peaks Filename at UCSC Genome Browser or GEO series number
TAL1 G1E-ER4 + E2 4,915 wgEncodePsuTfbsG1eer4e2Tal1ME0S129InputPk.broadPeak.gz
GATA1 G1E-ER4 + E2 13,123 wgEncodePsuTfbsG1eer4e2Gata1aME0S129InputPk.broadPeak.gz
EP300 MEL 31,342 wgEncodeSydhTfbsMelP300IggrabPkV2.narrowPeak.gz,
wgEncodeSydhTfbsMelP300sc584IggrabPk.narrowPeak.gz
SMAD1 G1E-ER4 + E2 + BMP4 1,586 GSE29193
H3K4me1 G1E-ER4 + E2 105,231 wgEncodePsuHistoneG1eer4e2H3k04me1ME0S129InputPk.broadPeak.gz
H3K4me3 G1E-ER4 + E2 72,495 wgEncodePsuHistoneG1eer4e2H3k04me3ME0S129InputPk.broadPeak.gz
H3K27me3 G1E-ER4 + E2 53,587 wgEncodePsuHistoneG1eer4e2H3k27me3ME0S129InputPk.broadPeak.gz
H3K9me3 G1E-ER4 + E2 69,929 wgEncodePsuHistoneG1eer4e2H3k09me3ME0S129InputPk.broadPeak.gz
H3K27ac G1E-ER4 + E2 31,535 GSE61349
DNaseI hypersensitivity G1E-ER4 + E2 93,705 wgEncodePsuDnaseG1eer4S129ME0Diffd24hPkRep1.narrowPeak.gz
Note: G1E-ER4 + E2: cells treated with estradiol for 24 h.
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directly in a promoter versus in an enhancer that is lo-
cated adjacent to the promoter. Hence, all the TAL1 OSs
were considered candidates for enhancers, even though
some could also be in DNA segments active as promoters.
From the set of 4,915 DNA segments bound by TAL1, 70
(Additional file 1: Tables S2 and S3) were tested for en-
hancer activity after transient transfection in K562 cells,
which have properties of erythroid and megakaryocytic
cells [48]. The 70 were chosen randomly from eight clus-
ters of TAL1 OSs characterized by additional epigenetic
features, as described in the next section. Each TAL1 OS
was tested for the ability to increase luciferase expression
from a reporter gene in multiple experiments [12,49], with
good reproducibility between both biological and tech-
nical replicates (Figure 1C; Additional file 2: Figure S2A).
The results, presented as box plots summarizing all the
data for each of the 70 tested TAL1 OSs (Figure 1D; values
are in Additional file 1: Table S3), showed that 39 (56%)
produced at least a twofold increase. Many were strongly
active, with 26 giving at least a threefold increase, and the
most active one generating a median effect of 23-fold.
Activity of another 7 (10%) TAL1 OSs fell in a ‘threshold
zone,’ which was less than the twofold needed to be de-
clared an enhancer by this assay, but greater than 1.5-fold,
which is over three standard deviations above the median
of the negative controls. The remaining 24 TAL1 OSs
were not active in this enhancer assay. While the transient
transfection assay reveals the ability to increase expression
from a plasmid that acquires some aspects of chromatin
structure [50], the DNA does not integrate into chromo-
somes, and the activity is assayed in a single-cell type.
We then turned to assays for tissue-specific enhance-
ment in transgenic mouse embryos [5]. A large number
of human and mouse candidate cis-regulatory modules,
predicted by interspecies conservation of noncoding se-
quences [5], EP300 occupancy [7], or other features [51],have been tested for the ability to increase expression of
a beta-galactosidase reporter gene driven by a minimal
promoter in a tissue-specific manner at embryonic day
11.5 of mice. Of the 4,915 erythroid TAL1 OSs, 66
(mouse DNA fragments or their human orthologs) have
been tested in the mouse transient transgenic assay, as
recorded in the VISTA Enhancer Browser [52]. Remark-
ably, 43 of these (65%) were reproducibly active in one
or more tissues, with the greatest number in heart and
midbrain (Figure 1E-G; Additional file 1: Table S4).
Nine TAL1 OSs were tested in both assays. All nine
were active in a distinct set of tissues, and seven of the
nine were also active in the transient transfection assay
(Figure 1H; Additional file 2: Figure S2B). Thus, our
assessment of enhancer activity for the TAL1 OSs is
robust, with a large majority of the tested DNA fragments
active in both assays.
Signal strength does not help distinguish TAL1 OSs active
as enhancers
The TAL1 OSs share many features associated with
enhancer activity (Figure 1B), and thus we searched for
additional factors that could distinguish the enhancer-
active ones from those that are inactive in these assays.
We hypothesized that the level of signal for binding by
known TFs or HMs associated with regulation could dis-
tinguish enhancer-active TAL1 OSs from inactive ones.
Given the strong association of gene induction with co-
occupancy by GATA1 with TAL1 [32-35], we computed
the level of ChIP-seq signal for both GATA1 and TAL1 in
each of the 4,915 TAL1 OSs. Note that all DNA segments
have TAL1 signal above the threshold for peak calling, but
some have GATA1 signals below such a threshold. For each
TAL1 OS, the signal levels for H3K4me1 and H3K4me3
HMs were also computed and expressed as the log base 2
of the ratio of monomethylation to trimethylation of H3K4
[20,47]. The resulting data matrix was then organized into
Figure 1 Genome-wide prediction of TAL1 OSs as enhancers. (A) Epigenetic marks overlapping a TAL1 peak within Gypc. Tracks displayed on the
UCSC Genome Browser [109] show, in descending order, the DNA segment tested for enhancer activity, occupancy by TAL1 and GATA1, the gene model,
DNase hypersensitive sites in G1E cells, G1E-ER4 cells treated with estradiol, and mouse primary fetal liver-derived early erythroid progenitors (EPC CD117+,
CD71+, TER119-) and differentiating erythroblasts (EPC CD117-, CD71+, TER119+). (B) Overview of ChIP-seq data for epigenetic features at
TAL1 peaks. (C, D) Erythroid enhancer activity of TAL1 OSs in a transient transfection assay. (C) Biological replicates (two different days of
transfection, Rep1 and Rep2) and technical replicates (eight for each biological replicate) of the enhancer assays of a negative control vector and an
expression vector containing TAL1 OS from the Gypc intron. (D) Enhancer assay results for 70 TAL1 OSs, ordered by activity. The distribution of results
for each TAL1 OS is shown as a box plot, with the internal line indicating the median value. Boxes for inactive TAL1 OSs are shaded blue, those in the
threshold zone are pink, and those with activity are shaded red. (E, F, G) Tissue-specific enhancer activities of TAL1 OSs in transgenic mouse assays.
(E) Partitions of 66 TAL1 OSs by enhancer activity. (F) Four examples of whole mouse embryos with in vivo enhancer activity at E11.5. (G) Distribution
of tissues showing enhancement by the TAL1 OSs. For TAL1 OSs active in multiple tissues, each tissue was counted for the distribution. (H) Comparison
of the results of the two enhancer assays on nine TAL1 OSs. Stained mouse images are from the VISTA Enhancer Browser.
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of the three features using k-means clustering, k = 8
(Figure 2A; Additional file 1: Table S5). The clusters
had distinctive features that may be expected to correl-
ate with differences in enhancer activity. For example,cluster 1 had a higher level of H3K4 trimethylation than
monomethylation, characteristic of regions proximal to
promoters, and indeed, a majority of TAL1 OSs in cluster 1
were within 1 kb of a TSS (Additional file 2: Figure S3A).
Clusters 3 to 8 had properties associated with enhancers,
Figure 2 Clustering TAL1 OSs based on epigenetic features. (A) TAL1 OSs clustered by the ChIP-seq signals of H3K4me1 and H3K4me3 (log2 of the
ratio), TAL1, and GATA1 (k-means clusters, k = 8). (B) Enhancer activities of TAL1 OSs tested by transient transfection assays in K562 cells, grouped in
clusters by epigenetic features. The names of individual TAL1 OSs are given along the x-axis, and the percent active in each cluster is listed. The
distinctive properties of each TAL1 OS cluster are summarized in the three colored bars, derived from Figure 2A. (C) Activities of TAL1 OSs grouped
in clusters by epigenetic features, shown for both enhancer assays: transient transfection into K562 cells (left) and transgenic mice at E11.5 (right).
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methylation (Figure 2A) and genomic location distal to the
closest TSS (Additional file 2: Figure S3A). DNA segments
in clusters 1, 4, and 5 had high signals for GATA1 occu-
pancy and thus would be considered particularly strong
candidates for erythroid enhancers. Almost all TAL1 OSs
in each cluster were in DHSs, and a majority were also
bound by EP300, with the exception of cluster 2 (Additional
file 2: Figure S3C). Likewise, the currently known erythroid
CRMs [36] were distributed among all clusters, except for
clusters 2 and 8 (Additional file 2: Figure S3B).Our hypothesis predicts that the rate of finding active
enhancers should vary significantly among the clusters.
The 70 TAL1 OSs tested for enhancer activity in transi-
ent transfections were randomly chosen from each of the
eight clusters, with 7 to 11 DNA segments from each
(Additional file 1: Tables S3 and S5). Unexpectedly, the
frequency of positives did not differ dramatically among
most of the clusters (Figure 2B), ranging from 50% to
75% for almost all the clusters. The only exception is
cluster 8 with only a 30% success rate. Notably, the TAL1
OSs in this cluster have a very low level of GATA1
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GATA1 are less likely to be enhancers. Surprisingly, high
levels of TAL1 and GATA1 signal did not correlate with
higher frequency of enhancer activity. Cluster 4 had the
highest levels of TAL1 and GATA1, yet its rate of posi-
tives (50%) was lower than that of several other clusters.
Notably, a substantial majority of TAL1 OSs with lower
ratios of H3K4me1/H3K4me3 (clusters 1 and 2) and
proximity to a TSS (cluster 1) were active as enhancers in
the transient transfection assay. While many TAL1 OSs in
cluster 1 were expected to be promoters, the results show
that they also contain promoter-proximal enhancers.
Cluster 2 also had a preponderance of H3K4me3 over
H3K4me1, but only 28% of the TAL1 OSs in this cluster
were within 1 kb of an annotated TSS. Half of the tested
TAL1 OSs in cluster 2 were active as enhancers.
Examination of the level of TF binding signal or HM
without regard to the clustering patterns confirmed
that, for these DNA segments bound by TAL1, signal
strength does not correlate with activity. The correl-
ation coefficient R ranges from negative values for
TAL1 and H3K4me1 signal to a low positive value for
GATA1 signal (Additional file 2: Figure S4A). The three ac-
tivity categories (active, threshold, and inactive) showed
similar distributions of signal intensity for TAL1 binding,
GATA1 binding, and the ratio of H3K4me1 to H3K4me3
(Additional file 2: Figure S4B). This absence of a correlation
between enhancer activity binding signal strength persists
even when the signals are evaluated at DNA intervals
called as peaks of TF binding (Additional file 2: Figure S4A
for TAL1 and S4C for GATA1). Likewise, the G + C
content of the tested TAL1 OSs DNA segments had
little discriminatory power; each activity class had
similar GC content (Additional file 2: Figure S3D). The
presence of EP300 at a TAL1 OS did help distinguish
active versus inactive in this assay but not dramatically.
The fraction of enhancer-active TAL1 OSs with EP300
(80%) was larger than the fraction of inactive TAL1
OSs with EP300 (61%) (Additional file 2: Figure S3E).
Moreover, among the TAL1 OSs in cluster 8, none of
the inactive regions were bound by EP300.
The limited effect of signal levels on success of predict-
ing enhancers (conditional on TAL1 occupancy) was also
seen for the transient transgenic mouse assays. The TAL1
OSs determined to be active enhancers in each of the
two assays were distributed similarly among the eight
clusters (Figure 2C; Additional file 1: Table S4). This
includes the lower frequency of successful predictions when
TAL1 is bound with little or no GATA1 (cluster 8).
Greater contribution of TF binding than HMs to
successful prediction of enhancers
In order to evaluate the contribution of multiple epigen-
etic features to the likelihood of a DNA segment beingan enhancer, we expanded our study to include 273 DNA
segments evaluated for enhancer activity by transfection
into K562 cells in this laboratory [12,24], including the
70 TAL1 OSs just described. This larger meta-analysis
is not restricted to any particular TF occupancy or con-
servation pattern, and it includes several DNA segments
previously used as negative controls. Each of the 273
DNA segments were annotated by the presence or absence
of ten features, specifically DHSs, binding by TAL1 or
GATA1, or presence of H3K4me1, H3K4me3, H3K27ac,
H3K27me3, or H3K9me3 (all in G1E-ER4 cells induced for
24 h with estradiol), binding by EP300 in MEL cells [46], or
presence of CAGE (cap analysis of gene expression) tags
[53]. The level of enhancer activity (fold change) and cat-
egory (active, threshold, or inactive) was also recorded in
the data matrix (Additional file 1: Table S6).
We confirmed that four commonly used epigenetic pre-
dictors of enhancers, DHSs, H3K4me1, H3K27ac, and oc-
cupancy by the co-activator EP300, were strongly positively
associated with enhancement (Figure 3A). The range of ac-
tivities is consistently and significantly higher for DNA seg-
ments with these features than those without them, and
EP300 had the strongest effect. Importantly, the presence
of either TAL1 or GATA1 was also highly predictive of en-
hancer activity, with median activity levels comparable to
that for EP300-positive DNA segments (Figure 3A;
Additional file 1: Tables S6 and S7). The presence of
H3K4me3 was associated with higher activity in this
assay, perhaps reflecting promoter-proximal enhancers.
CAGE tags also were associated with enhancer activity
(Figure 3A), and the frequency of observing CAGE tags at ac-
tive enhancers (49%) was almost twice that for non-active
DNA segments (27%; Additional file 2: Figure S5). Moreover,
the median values of enhancer activities for TF-bound DNA
segments (twofold change in activity or greater; Figure 3A)
were consistently higher than those for DNA segments
with active HMs, DHSs, or CAGE tags (ranging from 1.67 to
1.87). As expected, the repressive HMs were not associated
with enhancer activity (Figure 3A; Additional file 1: Table S7).
In order to examine the prevalence of these epigenetic
features across the accessible chromatin landscape, we de-
termined their presence or absence in the 93,705 DHSs
ascertained in 24-h-induced G1E-ER4 cells [36,54]. Only a
small fraction of DHS were bound by the TFs associated
with enhancement. Specifically, 11% (10,012) were bound
by GATA1 and/or TAL1, and 16% (15,456) were bound
by GATA1, TAL1, and/or EP300 (Figure 3B). In con-
trast, a much higher proportion (74%) of the DHSs carried
at least one active histone mark (H3K27ac, H3K3me1, or
H3K3me3). A majority (58%) of DHSs were in chromatin
with an activity-associated HM but not bound by any of
the three TFs. Reflecting the use of prior knowledge about
enhancer-associated features in selecting DNA segments
for experimental tests, a larger proportion of DHSs actually
Figure 3 Contributions of TF binding versus histone modification enrichment to enhancer activity. (A) Distributions of enhancer activities of 273 DNA
segments marked by each feature individually. The asterisks indicate statistically significant difference in activity between the presence and absence of
the features. (B) Proportions of DHSs in 24-h-induced G1E-ER4 cells (total of 93,705) and tested DNA fragments that overlap DHSs (total of 188) with
each feature combination. (C) The percentage of active enhancers captured by each set of features and the success rate of tested DNA segments (total
of 273) with each feature combination.
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Despite the small fraction of all DHS bound by the exam-
ined TFs, such binding was effective at capturing most
(90% to 95%) of the 90 active enhancers in the set of 273
tested DNA segments (Figure 3C). Furthermore, the rate at
which TF-bound DNA segments were active as enhancers
was over 50%. In contrast, activity-associated HMs in the
absence of TF binding did not capture known enhancers,
nor were they good predictors of activity.
We then computed the sensitivity (Sn) and specificity
(Sp) of features, individually and in combination, for
predicting enhancers active in the transient transfection
assay. For 74 combinations of epigenetic features (in-
cluding individual features; Additional file 1: Table S8),
the tested DNA segments that had a given set of features
were considered the positive predictions for enhancer
activity, and the remaining tested DNA fragments were
considered negatives. These predictions were then evalu-
ated by the results of the enhancer assay, thereby separ-
ating the positive predictions into true and false
positives and the negative predictions into true and false
negatives. Thus, we could calculate the Sn and Sp for
enhancer prediction by each set of features, utilizing the
information from all 273 tested DNA fragments for each
set of features. Unless explicitly stated (for example,
HMs without TF binding), a DNA segment was evalu-
ated as having a given feature regardless of the status of
other features. We displayed the results in ROC (re-
ceiver operating characteristic) graphs (Figure 4), so that
the best discriminators generated points in the upper left
of the graph, whereas feature(s) with low discriminatory
power generated points along or to the right of the diag-
onal. The sets of features were described by the mini-
mum requirement for inclusion, so that, for example,
DNA segments with both TAL1 and H3K27ac were a
subset of the group of DNA segments with TAL1.
We found that TF binding was a better predictor of en-
hancer activity than activity-associated HMs, primarily be-
cause of the higher specificity of the former (Figure 4A);
this was seen both for individual features and combinations.
The two best single discriminators were EP300 binding and
TAL1 occupancy; they were almost indistinguishable in Sn
(77% and 74%, respectively) and identical in Sp (69%).
Combinations of TF binding and activity-associated HMs
also had good performance. Considering histone modifica-
tions without regard to TF binding gave high Sn (0.89 for
H3K4me1 or H3K27ac) but low Sp (0.31 for H3K4me1 and
0.46 for H3K27ac). Importantly, the presence of activity-
associated HMs in the absence of TF binding performed
very poorly, with a Sn of 0.01 to 0.02. The presence of TF
binding in the absence of activity-associated HMs also gave
a low Sn (0.02), but this arrangement was rare (only three
DNA segments in the 273 examined). The ROC of all the
examined feature combinations together shows that manycombinations of TFs and HMs have good performance,
forming a cluster in the upper left of the graph (Figure 4B).
The discriminatory power of each feature and combination
is better resolved in the dot plot (Figure 4C), which displays
the distance of each (1-Sp, Sn) point from the ideal of (0,1).
Over 15 features individually or in combination had an
equivalently short distance (that is, good discriminatory
power). Two of the strongest discriminators were binding
by TAL1 or by EP300. Combining binding by either TF
with HMs such as H3K27ac or H3K4me1 gave only a very
small increase in power. Having H3K4me3 as a feature low-
ered the discriminatory power (Figure 4C). DHS or CAGE
tags individually had some discriminatory power but con-
siderably less than TF binding. Repeating the ROC analysis
on the subset of 188 tested DNA segments that are also
DHS gave similar results for the discriminatory power of
these epigenetic features (Additional file 2: Figure S6;
Additional file 1: Table S9). For the large majority of feature
combinations, adding DHS had no impact on Sn or Sp,
although for a small minority the Sp was increased.
The primacy of TF occupancy in determining enhan-
cer function is a robust result. We extended our analysis
to include the recent results of massively parallel re-
porter assays (MPRAs) on 320 candidate enhancers with
GATA motifs [27] and 1,499 candidate enhancers [28].
We annotated each tested candidate enhancer for occu-
pancy by EP300, TAL1, GATA1, and/or GATA2 in K562
cells and then evaluated whether presence of TF binding
associated with strength of enhancement. In both data-
sets, candidate enhancers that were bound by one or
more of the TFs drove significantly higher levels of ex-
pression than those were not bound (P value = 1.5E-12
and 4.6E-05 for datasets from [27] to [28], respectively,
using the Welch two sample t-test) (Figure 5; effects for
each TF are shown in Additional file 2: Figure S7).
Candidate regulators of TAL1-bound active enhancers
We hypothesized that additional protein binding to the
TAL1 OSs may contribute to their activity, which pre-
dicts that binding site motifs for such proteins would be
present at significantly different frequencies in active versus
inactive groups of TAL1 OSs. We used the Discriminating
Matrix Enumerator program version 2, DME2 [55], to iden-
tify differentially enriched motifs, analyzing separately the
sets of TAL1 OSs tested in each assay (Additional file 1:
Figure S8A). The highest scoring DME2 motifs in each of
the resulting sets of enriched motifs were used to search
through two databases of known motifs, JASPAR [56] and
UniPROBE [57], using the motif comparison tool TOM-
TOM [58] (Additional file 1: Tables S10 to S13). Further in-
vestigation of the motifs with good statistical support that
were enriched only in active or inactive TAL1 OSs
(Additional file 1: Table S14) revealed five particularly
informative motifs from this analysis. Motifs enriched
Figure 4 Meta-analysis of contributions of epigenetic features to enhancer activity. The sensitivity and specificity of epigenetic features singly and
in combination for prediction of enhancer activity were evaluated for 273 DNA segments tested in transient transfection assays. The results
are displayed as a receiver-operator characteristic (ROC) graph. The graphs in (A) show the results for informative groups of features, and (B) shows the
results for all combinations of features. Abbreviations and color code are defined in panel (B). The top eight discriminators with the best performance
(dots in the upper left) are labeled in (B). (C) Dot plot illustrating the distance of 74 feature and feature combinations to the point with the
best discriminator performance (Sn = 1 and Sp = 1).
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tifs for several proteins not previously implicated in en-
hancement by TAL1, including members of the IRF,
STAT, FOX, and SMAD families of proteins (Figure 6A).
Conversely, motifs that were enriched in TAL1 OSs not
active as enhancers included the binding site motifs for
HOXD10 and REST (Figure 6B).
For these proteins implicated in enhancer activity by
motif enrichment, we searched for evidence that theywere co-localizing with TAL1 and potentially played a
role in enhancement. Our search was facilitated by the ex-
tensive compilation of ChIP-seq datasets in the CODEX
resource [59]. Members of the SMAD family of proteins,
which mediate TGF-beta- and bone morphogenic protein
(BMP)-signaling pathways, were particularly attractive
candidates. The receptor-regulated SMADs, including
SMAD1 and SMAD3, form a trimer with a co-SMAD to
regulate the expression of target genes [60], but the
Figure 5 Association of TF binding with strength of enhancement
in high-throughput enhancer assays. Distribution of expression levels
of (A) 320 DNA segments with GATA motif instances that are in
enhancer chromatin states in K562 cells [27], and (B) 1,499 DNA
segments that are in enhancer chromatin states in K562 cells [28]. The
assayed DNA segments were categorized as TF bound or TF unbound
based on overlap with ChIP-seq peaks for EP300, TAL1, GATA1, or GATA2
in K562 cells [51]. The distribution of enhancer activities (from [27] and
[28]) in each category is presented as box plots. The total numbers of
DNA segments in each category are given at the bottom of the plots.
The horizontal internal line and the diamond shape indicate the median
and mean of enhancer activity in each category, respectively.
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to bind effectively to DNA and activate transcription
[60,61]. Recent studies showed that in response to BMP4
treatment, SMAD1 tends to co-bind to DNA with the mas-
ter erythroid GATA factors in G1E and induced G1E-ER4
cells [38]. By integrating these ChIP-seq data for SMAD1
occupancy [38] into our analyses, we found that SMAD1
occupancy overlaps extensively with not only GATA1 but
also TAL1 occupancy (Figure 6C). Seventy-six percent of
SMAD1 OSs overlap with either GATA1 OSs or TAL1
OSs, and 795 sites were bound by all three proteins. An ex-
ample of co-occupancy is shown in Figure 6F. A similarly
large overlap between SMAD1 peaks (55%) and TAL1 OSs
or GATA1 OSs was seen in human K562 cells (Additional
file 2: Figure S9A). Functional term enrichment analysis
by GREAT (Genomic Regions Enrichment of Annotation
Tool; [62]) showed that the presumptive gene targets of
SMAD1 in induced G1E-ER4 cells are enriched for
hematopoietic activities, including heme biosynthetic
process, regulation of myeloid cell differentiation, erythro-
poiesis, erythrocyte morphology, and erythrocyte cell
number (Additional file 2: Figure S10A and S10B).
Inclusion of SMAD1 binding with TAL1 occupancy
improved the accuracy of enhancer prediction. All the
TAL1 OSs that were co-bound by SMAD1 in G1E-ER4
cells were also bound by GATA1 (Figure 6C), and thus
we evaluated TAL1-GATA1 co-occupied DNA segmentsfor enhancer activity with or without SMAD1. Of the 27
TAL1-GATA1-SMAD1 co-bound regions tested for en-
hancer activities in mouse transgenic assays, 21 (78%)
showed reproducible in vivo enhancer activity in different
tissues (Figure 6D; Additional file 1: Table S15). In contrast,
of the 42 TAL1-GATA1 co-bound segments that were
not bound by SMAD1, a smaller percentage (55%) were
active in this assay (Figure 6D). A similar positive effect
of SMAD1 occupancy along with TAL1 and GATA1
co-occupancy on accuracy of enhancer predictions tested
in transgenic mice was observed when ChIP-seq data from
human K562 cells was used to identify candidate enhancers
(Additional file 2: Figure S9B). The presence or absence of
SMAD1 had little effect on the tissue distribution of enhan-
cer activity of TAL1 and GATA1 co-occupied DNA seg-
ments (Additional file 2: Figure S11A and S11B).
The positive effect of including SMAD1 in enhancer
predictions was also observed in results from transient
transfections of hematopoietic cells. Inclusion of SMAD1
binding along with TAL1 and GATA1 binding produced
a success rate of 71% in our transfection assays (Figure 6E,
Additional file 1: Table S6). Moreover, partitioning the
expression results of 1,499 candidate enhancers tested in a
massively parallel reporter assay [28] by TF occupancy in
K562 cells showed that DNA segments bound by TAL1 and
SMAD1 gave a higher distribution of expression levels than
those not bound by the two proteins (Additional file 2: Fig-
ure S9C). Of the 30 SMAD1 peaks that overlap with active
enhancers bound by TAL1, the DNA sequences of 7 (23%)
have matches to the SMAD motif (Additional file 1: Table
S16), suggesting that in these cases the recruitment of
SMAD1 involved direct binding to its preferred binding site
in DNA, which is consistent with the motif enrichment.
The other proteins whose binding site motifs were
enriched in enhancer-active TAL1 OSs also overlapped
with TAL1 OSs but much less frequently than seen for
SMAD1 (Additional file 2: Figure S13). ChIP-seq binding
profiles for IRF2 have been determined in human proer-
ythroblasts [63], and 3% and 6% of these overlap with
TAL1 peaks determined in human proerythroblasts [64]
and K562 cells [51], respectively. Binding profiles have
been determined for the candidate proteins in many
non-erythroid cell types, and we present results on over-
laps with representatives of the other protein families.
STAT1 binding profiles have been determined in mouse
macrophages [65] and T cells [66]. Despite the fact that
these are not erythroid cells, in both cases, about 1% of
the STAT1 peaks overlap with TAL1 OSs determined in
G1E-ER4 cells. Likewise, about 2% of the binding sites
for FOXO1 in mouse CD4+ cells [67] and SMAD3 in
mouse B cells [68] overlapped with TAL1 OSs in G1E-ER4
cells. Examples of the binding signals for many of these
proteins are shown for the Gypc gene (Figure 6F for mouse;
Additional file 2: Figure S12 for human). In each of
Figure 6 Candidate regulators of TAL1-bound active enhancers. (A) Motifs that distinguish TAL1 OSs that are active enhancers from those that are
inactive. The motif discovered by DME2 is given on the first line of each box, followed by the known TF binding site motifs discovered by TOMTOM,
all shown as aligned logos. (B) Motifs that distinguish TAL1 OSs that are inactive enhancers from those that are active. (C) Venn diagrams show
genome-wide overlaps between SMAD1, TAL1, and GATA1 peaks in erythroid lineage, G1E-ER4 + E2 cells. Number of regions bound by these peaks is
shown. (D) Power of SMAD1 binding on enhancer activity in transgenic mice. (E) Heat map depicting the effect of co-localization of SMAD1, TAL1,
and GATA1 in different combinations on success rate in vitro enhancer assay (transfections into hematopoietic cell line). (F) Shown is an intron of the
Gypc gene in the mouse genome, along with ChIP-seq binding profiles for TAL1 (GEO sample numbers: GSM746555-56, GSM746571-72, GSM746583_84),
GATA1 (GSM453997, GSM417015, GSM1151146, GSM746581-82), GATA2 (GSM641911, GSM722387), GATA4 (GSM558904), SMAD1 (GSM722388,
GSM722391), STAT1 (GSM994528), STAT5 (GSM652878), STAT5b (GSM1014575, GSM671418), IRF4 (GSM1004833_35, GSM1004821), and FOXO1
(GSM1131775, GSM998924) in hematopoietic cells, in descending order. ChIP-seq binding signals (bigwig) were obtained from CODEX [59].
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STAT1, FOXO1, or SMAD3, a small number have been
tested for enhancer activity in transgenic mice, trans-
fected cells, or both. In all cases, a substantial propor-
tion of the tested TAL1 OSs was active, ranging from
47% to 100% (Additional file 1: Table S17).
Inclusion of SMAD1 and CAGE tags refine enhancer
prediction for higher accuracy
The previous analysis examined the impact of feature
combinations usually without regard for other features;each tested DNA segment was included as either a posi-
tive or negative prediction for each feature combination.
In a complementary approach, we assigned each of the
273 tested DNA segments to only one of several discrete
groups, and each group was defined by a consistent pat-
tern of the presence of some features and absence of
others. We also added SMAD1 binding data [38] based
on the positive results described in the previous section.
We used density-based spatial clustering of applications
with noise (DBSCAN; [69]) to identify homogenous clusters
while placing the less informative non-homogenous
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25 homogenous clusters of feature combinations that
contribute differentially to the response of enhancer ac-
tivity (Figure 7; Additional file 1: Table S6). Each cluster
was then evaluated by the prevalence of three enhancer
activity categories (active, threshold, inactive) and their
median fold change in activity in the enhancer assay.
Our analysis of the enhancer activity within these
discrete groups of DNA segments not only shows the
importance of TF binding as a predictor of enhancers
but also reveals highly accurate combinations. Nine fea-
tures associated with transcriptional activity can be con-
sidered positive: DHS, TAL1, GATA1, EP300, SMAD1,Figure 7 Combinations of epigenetic features and their association with enhan
results for 1 of the 273 tested DNA segments. The presence or absence of the 1
tested segments were organized into clusters by DBSCAN [69] using the binary
categorized by activity in the transient transfection assay, denoted by a colored
Success rates (B) and activities (C) in enhancer assays on 273 DNA segments in
to identify enhancers.H3K4me1, H3K4me3, H3K27ac, and CAGE tags. The
other two, H3K27me3 and H3K9me3, can be considered
negative. The positive features tended to occur together,
and these displayed a high frequency of active enhancers
(Figure 7A). Cluster 1, containing all the positive features,
and cluster 2, lacking only the promoter-associated mark
H3K4me3, both had remarkably high frequencies of
active enhancers, that is, 86% (12 out of 14) and 80% (4
out of 5), respectively (Figure 7A,B). The median fold
changes in activity were also strikingly high, 2.9-fold and
3.2-fold, respectively (Figure 7C). Clusters 3 to 7 lacked
SMAD1 and/or CAGE tags, and while they had high
frequencies of active DNA segments (46% to 67%), theycer activity. (A) Each row of the diagram shows the features and activity
1 epigenetic features is represented by grey and white, respectively. The
representation of the epigenetic features. Each tested DNA segment is also
entry in the last three rows (red = active, pink = threshold, blue = inactive).
each cluster formed by DBSCAN. (D) Power of SMAD1 and TAL1 binding
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dian fold change was also lower. Clusters 10 to 14 exclude
one or more additional TFs but retain the positive his-
tone modifications and DHS, and these have lower fre-
quencies of active enhancers and lower median fold
changes. Thus, the presence of TFs had a strong posi-
tive effect, and the combination of all four TFs along
with positive histone modifications, CAGE tags, and
DHSs gave the highest frequency of accurate enhancer
predictions. The combination of TAL1 plus SMAD1
plus CAGE tags (which always co-occurred with DHS,
GATA1, and EP300) was a particularly strong predictor
of enhancement (Figure 7C).
In contrast, DNA segments with positive histone mod-
ifications and DHS but no TF occupancy (clusters 15,
16, 19, and 22) were rarely active as enhancers. The median
enhancer activity of the DNA segments ranged from 0.9 to
1.3 (Figure 7C), and the frequency of enhancers ranged
from 0% to 20% (Figure 7B). As expected, DNA segments
with none of the ten features (cluster 25) or with only nega-
tive histone modifications (clusters 23 and 24) were rarely
active in the enhancer assay.Preservation of binding site motifs is a positive predictor
of enhancement
The overall level of sequence conservation surrounding
the TAL1 OSs, based on interspecies comparisons, was
not strongly associated with activity in either enhancer
assay. The large majority of both sets of TAL1 OSs,
tested in transient transfections or in transgenic mice,
had quite low levels of conservation aggregated across
the bound segments (Additional file 2: Figure S14AA;
Additional file 1: Table S18). The level of conservation,
estimated by the phastCons score [70] and phyloP [71],
had weakly positive associations with level of activity in
the transient transfection assay (correlation coefficients
from linear regression R = +0.173 and R = +0.015, re-
spectively, Additional file 2: Figure S14B).
We expected that evolutionary constraint would be most
intense on the protein binding sites, and thus we focused
on preservation of a TF binding site motif between mouse
and human to monitor more localized constraint. The
GATA motif (WGATAR) is the major sequence determin-
ant of GATA1 binding, and it is also the TF binding site
motif most strongly associated with TAL1 occupancy,
reflecting a strong role of GATA factors in directing the
binding of TAL1 [37,72]. Individual instances of this motif
in the TF-bound sites tested in enhancer assays were
categorized as having (a) a GATA motif preserved be-
tween mouse and human, (b) a GATA motif in mouse but
not human, or (c) no GATA motif in mouse (Additional
file 2: Figure S15A and B). Each TF OS was then assigned
hierarchically to categories a to c, so that a DNA segmentwith both preserved and lineage-specific motifs was placed
in the preserved category (Additional file 1: Table S19).
Evaluation of the enhancer activity for the TF OSs in each
motif-conservation category revealed a positive association
with preservation of the GATA binding site motif. The dis-
tribution of enhancer activities was significantly higher for
DNA segments with a preserved motif than for those in
which the motif is not preserved; this is the case both for
151 DNA segments bound by GATA1 (P value = 0.017)
and for 115 DNA segments bound by both GATA1 and
TAL1 (P value = 0.038) (Additional file 2: Figure S15B).
Furthermore, the frequency of observing enhancer activity
was higher for the TF-bound DNA segments with the
preserved GATA motif (60% to 65% compared to 41% to
44% for non-preserved motifs in the GATA1-bound and
GATA1-TAL1 co-bound DNA segments, respectively).
Discussion
Importance of TF binding for accurate prediction
of enhancers
This study gives important insights into the relative con-
tributions of different epigenetic features to the identifica-
tion of active enhancers. Our examination of TAL1 OSs
showed that predicting enhancers based on occupancy by
a single critical TF was quite accurate, giving a success
rate of 56% in transient transfections of hematopoietic
cells and 65% in transient transgenic mice. Moreover, our
meta-analysis of 273 tested DNA segments showed that
TAL1 binding was as accurate for the prediction of en-
hancers as binding by the coactivator EP300. Binding by
either factor was the single feature with the greatest pre-
dictive power. Previous studies used other tissue-specific
transcription factors, GATA1 binding in erythroid cells
[24] and MYOD binding in muscle cells [25], to predict
enhancers but with lower success rates (confirmed for
GATA1 in our meta-analysis). Thus, binding profiles for
some TFs appear to be better predictors than others,
which raises the issue of what properties of TFs make
them effective as predictors of enhancers. A recent study
of gene activation by NOTCH1 complexes in T cells found
that the dynamically occupied DNA segments are in-
volved in regulation [73]. One interpretation of our results
is that TFs displaying a highly dynamic pattern of binding
across differentiation, such as TAL1 during hematopoiesis
[37], may be the better predictors of active enhancers. The
increased accuracy of enhancer prediction when TAL1
OSs are combined with SMAD1 occupancy may also re-
flect the effectiveness of dynamic binding as a predictor.
After activation by BMP signaling, SMAD1 co-binds with
lineage-specific master regulators such as GATA1 [38] and
TAL1 (this report). This binding by SMAD1 suggests a
high accessibility of the enhancer-active TAL1 OSs to bind-
ing by additional transcriptional activators, which is a prop-
erty expected for dynamically active TF-bound sites. The
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by CAGE tags (Figure 7A); this signature of transcription
could also reflect a dynamic state at the active enhancers.
The DNA segments bound by the TFs examined were
almost uniformly in chromatin with histone modifications
associated with activity [37,41], and thus including positive
epigenetic features such as H3K4me1 and H3K27ac modi-
fications [18,22] improved the accuracy of enhancer
prediction only modestly. Surprisingly, the level of methy-
lation at H3K4 did not appear to be a major determinant
of enhancer activity. Importantly, DNA segments associ-
ated with these HMs but with no binding by TAL1,
GATA1, EP300, or SMAD1 were almost never experimen-
tally validated as enhancers. This result suggests that
many DNA segments in chromatin with HMs associated
with activity are not directly or independently involved in
gene regulation.
Our conclusions help explain recent results using
MPRAs to evaluate the accuracy of enhancers predicted
by HMM-based integrations of histone modification
signals [26] in human cell lines. Kwasnieski et al. [28]
sampled 1,800 candidate enhancers predicted by HMM-
based chromatin states in K562 or H1 embryonic stem
cells and found that 11% and 26% of the predicted strong
and weak enhancers, respectively, were active in a reporter
gene transfection assay in K562 cells. Kheradpour et al.
[27] used the chromHMM strong enhancer predictions but
restricted their analysis to over 2,000 with matches to bind-
ing site motifs for cell-type specific transcription factors.
For candidate enhancers with motifs indicative of binding
by transcriptional activators in K562 and HepG2 cells, they
estimated that 42% and 26% of the candidate enhancers
were active when the binding site motifs were conserved or
nonconserved, respectively. The higher proportions that
were active when binding site motifs were conserved are
consistent with our conclusion that binding by a key TF is
the major determinant of enhancer activity. Indeed,
Kwasnieski et al. [28] found that candidate enhancers
that were bound by AP1 ascertained by ChIP-seq data,
[51] drove higher levels of expression that those are not
bound, confirming on a large scale the results of early
studies [74,75]. Furthermore, the lower proportions ac-
tive when TF occupancy was not inferred are consistent
with our observation that histone modifications with
TF binding excluded are poor predictors of enhancer
activity. The overall success rates reported with MPRAs
are consistently lower than those observed our work.
Further studies are needed to better understand the
factors contributing to these differences, such as sensi-
tivities of the assays, use of very short DNA fragments
in MPRAs, methods of ascertaining the predictions,
and effects of sample sizes.
While many studies point to the importance of the epi-
genetic features studied in our work, their quantitativecontributions individually and in combination are not
consistently agreed upon across several recent studies
[27-29]. We observe experimentally determined occu-
pancy by TFs or coactivators to be of primary importance,
and our re-analysis of the results of MPRA experiments
[27,28] shows a similar positive effect for TF occupancy.
Almost all active enhancers in our study are in accessible
chromatin, but the vast majority of DHSs lack binding by
enhancer-associated TFs, and DHSs include many ‘false
positive’ predictions for enhancers. In contrast, Kwasnieski
et al. [28] report DHS to be the strongest feature distin-
guishing active from inactive chromHMM enhancer pre-
dictions, while models built on TF ChIP-seq data perform
less well than those built on DHS or incorporating motifs.
We find that H3K27ac has good predictive power, in
agreement with Erwin et al. [29] but Kheradpour et al.
[27] find a local ‘dip’ in H3K27ac to be a strong predictor,
while Kwasnieski et al. [28] find that lower levels of
H3K27ac are associated with active enhancers. These dif-
ferences may be more apparent than real, and we predict
that further experiments and consistent analyses with
common criteria for evaluating predictive power will re-
veal more agreement among results. While the contribu-
tions of the various epigenetic features have not yet been
definitively determined, the primary importance of TF
binding is a robust result.
Motif enrichment analyses coupled with comparisons to
genome-wide binding profiles identified additional proteins
that may co-bind with TAL1 and contribute to enhance-
ment during erythropoiesis, specifically SMAD proteins,
interferon regulatory factors (IRFs), the IRF partners
STAT2::STAT1, and forkhead box (FOX) family proteins.
The SMAD1 occupancy pattern [38] overlaps substantially
with that of TAL1 and GATA1 in both mouse and human
erythroid cells, and we showed that DNA segments bound
by all three TFs were active enhancers at very high rates
(86% for transient transfection and 78% for transgenic mice,
which are comparable to the highest success frequencies re-
ported for predicted mammalian enhancers [1,7]. Previous
studies of binding motifs [76], ChIP-seq binding profiles
[38], and protein interactions [77] had implicated SMAD
binding along with lineage-specific TFs in control of eryth-
roid regulation, and our analyses support a strong role for
the SMADs in TAL1-mediated enhancement. A similar
process has been proposed in which neuronal genes are ac-
tivated by the recruitment of SMAD1-EP300 by neurogenin
[78]; both neurogenin and TAL1 are bHLH TFs. About
one-quarter of SMAD1-TAL1 co-bound active enhancers
have SMAD binding site motif instances in the DNA
sequence, suggesting recruitment by direct binding of
SMAD1. However, in these and the remaining cases of
SMAD1 binding, a role for protein-protein interactions in
recruitment is also plausible. The involvement of IRFs in
TAL1-mediated enhancement is supported by previous
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ing by GATA1 [40] and erythroid enhancement [63]. Fur-
thermore, exploring the FactorBook of ENCODE ChIP-seq
data [79] showed that IRF1-bound sites in human K562
cells were enriched for co-binding by TAL1, GATA2, and
GATA1. Other studies have also implicated STAT proteins
[80-82] and FOX proteins [83-86] in erythropoiesis, as sug-
gested by our motif analysis. Genome-wide binding profiles
for members of these families have not yet been determined
in erythroid cells, and such datasets should be considered
as a high priority for future studies.
Most of the DNA segments bound by TAL1 have
not been strongly conserved since the divergence of ro-
dents and primates, just like many other DNA segments
associated with regulation [10,46,87-89]. However, when
we focus on the most informative transcription factor
binding motifs within these occupied DNA segments,
we find substantial preservation of the motif across
mammalian evolution in the active enhancers. This lends
further support to the conclusion that evolutionary con-
straint on enhancement activity leads to preservation of
the binding site motif [24]. The efficacy of preservation
of TF binding site motifs over large evolutionary distances
was demonstrated on a very large scale in mammals in a
recent MPRA study [27].
Insights from this study can be applied widely in en-
hancer predictions. An initial survey of the regulatory
landscape can be made with high sensitivity using DHS,
or an integrative modeling of histone modifications, or
both. However, this large collection of DNA segments in
accessible chromatin with enhancer-associated chroma-
tin states contains many false positives for enhancer pre-
dictions. Attention should be focused on the subset that
has strong evidence of occupancy by key TFs. For some
cell types, a master regulator is present at many of the
enhancers, such as TAL1 in erythroid cells, and ChIP-
seq data for that regulator will greatly improve the speci-
ficity of enhancer predictions. Further restriction to a
dynamically active subset, such as those bound even by
a different TF in response to a stimulus (for example,
SMADs in response to BMP signaling) and/or with evi-
dence of transcription (CAGE tags), may enrich for ac-
tive enhancers. A more broadly applicable feature is
occupancy by the general coactivator EP300. Previous
studies have shown that it is an accurate predictor of en-
hancers [7], and our study shows that it performs as well
as the cell type-specific TF TAL1 in erythroid cells.
Thus, ascertainment of EP300 in many cell types should
be a high priority for better prediction of enhancers
broadly. If experimentally determined binding data for
relevant TFs are not available, matches to TF binding
site motifs can be used. In this case, preference should
be given to the ones that are preserved over a broad evo-
lutionary span [24,27].Potential functions for enhancer false positives
The accuracy of enhancer prediction described in this work
is high, and for favorable combinations of features, it is
similar to some of the most effective predictors used previ-
ously [7,8]. While this result is encouraging, the fact re-
mains that substantial fraction of predictions did not show
activity in the assays. These predicted CRMs, active or in-
active, possess a striking array of features strongly associ-
ated with activity, such as TF occupancy, positive histone
modifications, and DNase accessibility. The success rates
for the CRM predictions are similar for both the transient
transfection and the transgenic mouse assays. Thus, it is
unlikely that one assay is seriously under- or over-counting
the biologically meaningful enhancers. Rather, we suggest
that other functional roles could be played by the predicted
CRMs that were inactive in the enhancer assays. These
other roles could include enhancement in tissues or at de-
velopmental stages not examined here. Future work with
high throughput assays [90-92] and activity-based selec-
tions [93-95] should interrogate a broader set of lineages
and conditions. Also, the predicted CRMs could have roles
in negative regulation [96]. The motif enrichment supports
this hypothesis. One of the motifs significantly enriched in
the TAL1 OSs that were not active as enhancers matches
the binding site motif for REST (NRSF). This is a known
repressor, and thus it is possible that co-occupancy of REST
with TAL1 may lead to down-regulation of expression. The
expression profile for NRSF in BioGPS [97] reveals strong
expression in early erythroblasts, supporting a potential role
for this repressor during erythropoiesis.
Interpreting the results of reporter assays
Both types of assays conducted in this study remove
DNA sequences from their chromosomal location and
place them close to a promoter and reporter gene, which
is then tested for expression either as a partially chroma-
tinized unintegrated plasmid (transient transfections) or
after random integration into a chromosome (transgenic
mouse). Thus, the natural genomic and chromosomal
context is lost, and this must be kept in mind in inter-
preting the results. The reporter assays used here do
provide valuable information about the activity of the
tested DNA segments in mechanistic aspects of gene
regulation, such as having a positive effect on expression
and thus an implication in enhancement. An under-
standing of the full biological role of each DNA segment
in its natural context will require genome editing ap-
proaches followed by deep phenotyping. With current
technologies, such studies examine small numbers of
regulatory regions (albeit with profound insights). Selec-
tion of targets for genome editing can be improved both
by increasing the accuracy of enhancer predictions and
by generating empirical evidence of activity in the higher
throughput (but context independent) assays. The data
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tivities, and they should be considered as part of a larger
effort to build genome-wide models of gene regulation
that incorporate information about chromosomal pos-
ition and cell context.
Activity of erythroid-ascertained enhancers in brain,
heart, and other tissues
Despite the fact that TAL1 occupancy and other epigenetic
features were ascertained in erythroid cells, the TAL1-
bound enhancers that were positive in transgenic mouse
embryos were active in brain, heart, and other tissues. The
time at which the transgenic embryos were examined (day
11.5) is earlier than the time of highly active hematopoiesis
in the mouse fetal liver (day 14.5 and later; [98,99]), which
explains the infrequent observation of fetal liver enhance-
ment. Explanations for expression in other tissues include
(a) activity of TFs present in erythroid cells that are also
present in other tissues, (b) activity of paralogous proteins
in other tissues that are related to the erythroid TFs and
bind to the same binding site motif, and (c) pleiotropic en-
hancers normally active in multiple tissues. These possibil-
ities are not mutually exclusive. For example, expression in
the brain could reflect all three, since (a) TAL1 is also
present in the brain, and (b) it co-operates with its paralog
TAL2 and GATA2 during GABAnergic neurogenesis in the
midbrain [100]. We recently showed that DNA segments at
which TF occupancy is conserved from mouse to human
tend to be active in multiple tissues, including examples of
activity in both erythroid cells and brain (possibility c, [46]).
In addition to pleiotropic enhancers, the ability of TAL1
OSs to enhance expression in the heart could reflect a role
in fetal cardiac endothelial cells in hematopoiesis. Defini-
tive hematopoietic stem cells are derived from a subset of
endothelial cells along the fetal dorsal aorta in the aorta-
gonad-mesonephrous region (AGM), and they migrate to
the fetal liver to establish high-level hematopoiesis
[99,101]. Recent studies indicate a close connection be-
tween early cardiac development and hematopoiesis. Early
cardiac progenitors express hematopoietic transcription
factors, such as TAL1 and GATA1 [102], and Nakano
et al. [103] demonstrated the hemogenic potential of
the heart tube endocardium. Furthermore, TAL1 binding
to primed enhancers in multipotential cardiovascular
mesoderm can repress cardiac fate and sustain hema-
topoietic fate [104]. Thus, some of the TAL1 OSs that are
active as enhancers in the transgenic fetal heart could rep-
resent enhancers that are normally active in hemogenic
cells within the developing heart. A possible example is a
TAL1 OS (peak ID: 1845 in Additional file 1: Table S1)
that corresponds to a mouse Runx1 intronic enhancer ac-
tive in hemogenic endothelial cells and hematopoietic
stem cells [105]. Further studies of epigenetic features in
specific tissues at day 11.5 of mouse development will helpelucidate the landscape of enhancers and their dynamics
during development [106].
Conclusions
TAL1 occupancy in erythroid cells was an accurate pre-
dictor of enhancer activity, and the accuracy was im-
proved by including binding by SMAD1 and evidence of
transcription (CAGE tags). Among epigenetic features
commonly used for enhancer prediction in mammalian
cells, binding by key TFs was more accurate than his-
tone modification patterns or chromatin accessibility.
Methods
ChIP-seq data for epigenetic features
ChIP-seq datasets for multiple epigenetic features [10,36,38],
numbers of peaks, and filenames for downloads are
given Table 1.
Data access
ChIP-seq data are deposited in GEO as the Series
GSE51338 and GSE61349, and they are available from
the Mouse ENCODE portal (http://mouse.encodedcc.org)
and the ENCODE portal (https://www.encodeproject.org).
Enhancer assays by transient transfection for K562 cells
Seventy DNA segments occupied by TAL1 in G1E-ER4
cells treated for 24 h with estradiol were amplified from
mouse DNA and cloned into a plasmid vector with the
firefly luciferase reporter gene driven by the HBG1 pro-
moter (Additional file 2: Figure S2A; Additional file 1:
Table S2; [12]). The test constructs were transiently
transfected into K562 cells in a 96-well plate using
0.14 μg of plasmid DNA containing firefly luciferase re-
porter and 0.00035 μg of co-transfection control plasmid
expressing Renilla luciferase in OptiMEM medium, add-
ing 0.14 μl of PLUS Reagent and 0.21 μl Lipofectamine
LTX per well. The cells were plated at 2.8 × 104 cells per
well. Each plasmid was transfected in quadruplicate
wells for each experiment, and each lysate after transfec-
tion was measured twice, for eight technical replicates.
Each plasmid was tested in at least two separate experi-
ments (biological replicates with transfections on differ-
ent days).
Cell extracts were harvested 48 h after the transfec-
tion, and firefly and Renilla luciferase activities were
measured in Promega’s dual luciferase assay. For each of
quadruplicate transfections, at least two measurements
were made on the cell lysates for a total of eight mea-
surements of both firefly and Renilla luciferases for each
construct in each experiment. The ratio of firefly lucifer-
ase activity of the test DNA to the Renilla luciferase ac-
tivity of the co-transfection control was normalized by
the ratio of firefly luciferase activity from the parental
vector to the Renilla luciferase activity of the co-
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fragments that have at least a twofold increase in activity
are considered as active enhancers (Additional file 1:
Table S3).
Enhancer assays in transgenic mice at embryonic
day 11.5
The set of TAL1 OSs were evaluated for enhancer activities
in mouse transgenic assays by mining data in the VISTA
Enhancer Browser (http://enhancer.lbl.gov/; [52]). In trans-
genic mouse assays, candidate DNA segments are cloned
into an Hsp68-promoter-LacZ reporter vector. The em-
bryos are generated and evaluated for reproducible LacZ
activity at embryonic stage E11.5 day. The predicted regions
showing reproducible expression in the same tissue in at
least three independent transgenic mouse embryos were
defined as positive enhancers. DNA segments tested in
transgenic mice (examining both mouse DNA segments
and the human orthologs of mouse TAL1 OSs) that over-
lapped with a TAL1 OS for at least 50% of the TAL1 OS
were included in the study (Additional file 1: Table S4).
Identification of significantly enriched motifs by
employing the computer program, discriminating matrix
enumerator
A computational method called Discriminating Matrix
Enumerator (DME2, beta version 2008_08_30) [55] was
used to identify overrepresented motifs of size 10 (described
by scoring matrices) in TAL1 bound enhancers and non-
enhancers identified by two enhancer assays: (1) ‘enhancers’
and ‘inactive’ regions determined by enhancer assay in tran-
siently transfected K562 cells; (2) ‘positive’ and ‘negative’ re-
gions identified by enhancer assay in transgenic mice.
Before DME2 was run, G +C contents of 4 datasets (en-
hancer, inactive, positive, negative) produced by each en-
hancer assay were checked. G +C contents (%) were
similar between foreground and background sets so that
DME2 could be run (Additional file 2: Figure S8B). DME2
software discovered the relative enrichment of position
weight matrices in the foreground set checked against the
background (Additional file 1: Tables S10 to S13). Discrim-
inatory power of each enriched motif was evaluated by the
relative enrichment score given by DME2 [55]. From the
200 motifs in each set (Additional file 1: Tables S10 to S13),
ten highest scored enriched DME motifs (Additional file 2:
Figure S8C) were analyzed further for matches to known
binding sites for mammalian transcription factors in the
motif databases, JASPAR Vertebrates, and UniPROBE
Mouse via motif comparison tool, TOMTOM [56-58].
One-hundred eight known motifs aligned by TOMTOM
(E value of <1) with good statistical were analyzed further.
56 motifs enriched in both the enhancer and non-
enhancer sets were removed. After filtering the aligned
motifs from the output of TOMTOM, transcription factorbinding sites for different families of proteins enriched in
only one category remained (Additional file 1: Table S14).
We also searched for occurrences of the SMAD bind-
ing site motif in the 30 SMAD1 peaks that overlapped
with active enhancers bound by TAL1. We used the
FIMO tool (Find Individual Motif Occurrences; MEME
version 4.10.0) run at a P value threshold of 0.001, with
default parameters, to identify matches to the weight
matrix that describes the SMAD motif overrepresented
at TAL1-bound active enhancers. This set of active en-
hancers includes those discovered by the transgenic
mouse assay and the transient transfection assay.
Clustering algorithms
The ChIP-seq signal strength of H3K4me1, H3K4me3,
TAL1, and GATA1 occupancy was calculated on each
TAL1 OS in G1E-ER4 cells treated with estradiol for 24 h
(Figure 2A). The TAL1 OSs were clustered into eight cat-
egories by k-means clustering (center-based) [107] based
on the log2 transformed ratio of H3K4me1 to H3K4me3
levels, the TAL1 occupancy levels, and the GATA1 occu-
pancy levels (Additional file 1: Table S5). Clustering at
higher values for k did not bring out additional distinctive
groups. Clustering was repeated 100 times, and only those
OSs that could be placed in the same clusters for at least 50
times were retained for the subsequent assays and display
(4,648 TAL1 OSs). In each iteration of clustering, the iden-
tity of a cluster was determined by the rank of its median
of H3K4me1/H3K4me3 ratios among all clusters. The clus-
tering was displayed by heat maps (Figure 2A). The color-
ing of the first column was set so that the intervals with
zero value (meaning the H3K4me1/H3K4me3 ratio equals
to one) were in black. The coloring of the third column
was set so that the intervals with value 0.11 were in pink.
This value was determined so that most (over 90%) inter-
vals with larger values were called as GATA1 OSs, and
most (over 90%) intervals with smaller values were not
called as GATA1 OSs.
In addition, the 273 DNA segments in the meta-analysis
were grouped by similarity in patterns of the presence or
the absence of ten epigenetic features that contribute differ-
entially to the response to enhancer activity using DBSCAN
(density-based spatial clustering of applications with noise)
(Additional file 1: Table S6; [69]). Twenty-five homogenous
clusters with the non-homogenous DNA segments were
displayed as a heat map (Figure 7). Presence of epigenetic
features in the DNA segments is shown grey in color,
and absence of the features is represented by white
color. We set the DBSCAN parameters: the size of the
ε-neighborhood of a DNA segment, Eps = 1, and the mini-
mum number of DNA segments showing homogenous pat-
tern of epigenetic features required to form a cluster,
minpts = 3. Homogenous clusters formed by DBSCAN
were numbered from 1 to 25 and colored by different
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put together in the lower part of the heat map.
Measuring discriminatory power of transcription factors
and histone modifications to identify enhancers
The discriminatory power of each positive feature and dif-
ferent combinations of them were evaluated by their sensi-
tivity (recall) and specificity values (Additional file 1:
Tables S8 and S9). The sensitivity is defined as the fraction
of the DNA segments with set of features that are active
enhancers. The specificity determines the fraction of the
DNA segments without set of features that are inactive.
Recent results of massively parallel reporter assays used
in this study were taken from two sources: Kheradpour
et al. [27] and Kwasnieski et al. [28]. The 320 DNA seg-
ments predicted by GATA motif instances within en-
hancer chromHMM states [27] and 1,499 candidate
enhancers predicted by ENCODE DNA segments by his-
tone modifications [28] were utilized to assess the accur-
acy of enhancers in the presence of TF binding (all from
K562 cell line). ChIP-seq Uniform Peaks for EP300,
TAL1, GATA1, and GATA2 in K562 cells from ENCODE
(hg19 database) were used to annotate each tested candi-
date enhancer for occupancy by these TFs. Out of 320
DNA segments, 247, 260, 119, and 242 [27] were bound
by EP300, TAL1, GATA1, and GATA2 in K562 cells,
respectively, while only 149, 154, 18 and 129 out of 1,499
DNA segments [28] were found to be bound by EP300,
TAL1, GATA1, and GATA2 in K562 cells, respectively.
The association between the presence of merged TF
binding and strength of enhancement for both datasets
was shown in Figure 5 (effects for individual TF are also
shown in Additional file 2: Figure S7).
Analyses of sequence conservation and motif
preservation
PhastCons [70] and PhyloP [71] conservation score of
each tested TAL1 peak were obtained from conservation
tracks of UCSC genome database. PhastCons scores
show the level of conservation of each nucleotide of a
conserved element in a multispecies alignment (on a
scale of 0, not conserved; to 1, fully conserved). PhyloP
score is a measurement of the conservation or diver-
gence of a specific alignment position (high positive
values point out purifying selection while negative scores
indicate acceleration). We calculated the average score
for each tested TAL1 peak that is centered on the mid-
dle of the called peak and extending 50 bp on each side
(Additional file 1: Table S18).
The CladiMo software package [108] was used to find
all WGATAR motif instances in alignments of multiple
mammalian genome sequences. Each DNA segment was
categorized as having (1) a GATA motif preserved be-
tween mouse and human, (2) a GATA1 motif in mouse,not human, or (3) no GATA motif in mouse (Additional
file 1: Table S18).
Additional files
Additional file 1: This file includes Tables S1 to S17.
Additional file 2: This file includes Figures S1 to S15 and the
legends of these figures.
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